Noile-Immune Biotech Crecimiento futuro
Future controles de criterios 0/6
Noile-Immune Biotech's earnings are forecast to decline at 15.5% per annum while its annual revenue is expected to grow at 0.7% per year. EPS is expected to decline by 15.1% per annum.
Información clave
-15.5%
Tasa de crecimiento de los beneficios
-15.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 10.7% |
| Tasa de crecimiento de los ingresos | 0.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 17 Sep 2024 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 319 | -1,483 | N/A | N/A | 1 |
| 12/31/2025 | 319 | -1,233 | N/A | N/A | 1 |
| 12/31/2024 | 319 | -903 | N/A | N/A | 1 |
| 6/30/2024 | 307 | -980 | -975 | -975 | N/A |
| 3/31/2024 | 310 | -976 | N/A | N/A | N/A |
| 12/31/2023 | 316 | -1,130 | -873 | -873 | N/A |
| 9/30/2023 | 319 | -1,268 | N/A | N/A | N/A |
| 12/31/2022 | 625 | -386 | N/A | N/A | N/A |
| 12/31/2021 | 100 | -795 | N/A | N/A | N/A |
| 12/31/2020 | 97 | -636 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 4893 is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: 4893 is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: 4893 is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: 4893's revenue (0.7% per year) is forecast to grow slower than the JP market (4.2% per year).
Ingresos de alto crecimiento: 4893's revenue (0.7% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 4893's Return on Equity is forecast to be high in 3 years time